COMPANY PROFILE

Sinocelltech

Sinocelltech is a biotech company that develops and manufactures recombinant proteins, monoclonal antibodies, and vaccines

Dongcheng District, ChinaBiotech & Life Sciences

Valuation $1–2.5B Last recorded · 2026

Revenue $100–500M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

At a glance

Status: Operational
Headquarters: Dongcheng District, China
Employees: 89
Open positions: 76
Dealroom signal: 3.5/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Vaccines, Biotech and Pharma, Hard Tech, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Founder mafia, market maps, research and news connected to this company by Dealroom

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
IPO✓Exit	Jun 2020	$181M	$181M	Undisclosed	—
SERIES AEquity / VC	May 2017	$28M	$110M	Qiming Venture Partners	—

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Sinocelltech website traffic

Latest recorded traffic for Sinocelltech is 620 monthly website visits, down 18.4% over the last three months.

Latest monthly visits620 3-month web change-18.4%

Monthly website visitsDec 2018–Jul 2026

Summary metrics are public; monthly history is available with a demoCompare with peers →

Openings linked to this company in Dealroom

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PHPharmaJetEnabling greater access to life-saving vaccines and pharmaceuticals globally	Golden, United States	Operational	32	$40M	$90M
BTBonacia (Hefei) Pharmaceutical TechnologyBonacia is a CRO company specializing in clinical research , focusing on professional services for clinical research of innovative drugs, biological drugs and vaccines, and empowering the research and development of new drugs through clinical trial cloud platforms and AI	China	Operational
ABAb&B BiotechFocuses on the research and development of innovative human vaccines and multivalent vaccines	Taizhou, China	Operational
ZEZeaVaxxDeveloping a plant-derived nanoparticle that can improve animal vaccines	West Lafayette, United States	Operational
NBNormax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness	Cork, Ireland	Operational
CICHA Vaccine InstituteTea vaccine research is a state-of-the-art biotech company developing vaccines and immunotherapys	South Korea	Operational
RMRVAC MedicinesMRNA platform company engaged in the research and development of innovative products such as vaccines for diseases	Singapore	Operational
CVCurevo VaccineCreating Next Generation Vaccines For Diseases Of Global Importance	Seattle, United States	Acquired